Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$2.99+0.22 (+7.94%)

Close on Nov 13, 2026Market cap $200.81MP/E –Yield –

Liminatus Pharma gross margin

Gross margin is gross profit as a percentage of revenue.

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?